A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

By Hollebecque A.   Deutsch E.   Massard C.   Gomez-Roca C.   Bahleda R.   Ribrag V.   Bourgier C.   Lazar V.   Lacroix L.   Gazzah A.   Varga A.   Baere T.   Beier F.   Kroesser S.   Trang K.   Zenke F.   Klevesath M.   Soria Jean-Charles  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1530-1538

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx^®) in combination with topotecan in patients with advanced malignancies

By Ghesquières Hervé   Faivre Sandrine   Djafari Latifa   Pautier Patricia   Lhommé Catherine   Lozahic Stéphanie   Djazouli Kamel   Armand Jean-Pierre   Raymond Eric  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 413-421

Springer Publishing Company

Access to resources Recommend Favorite

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

Blackwell Publishing

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies

By Argiris Athanassios  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1575-1584

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors

By Camacho Luis   Olson Jon   Tong William   Young Charles   Spriggs David   Malkin Mark  

Investigational New Drugs, Vol. 25, Iss. 2, 2007-04 ,pp. : 131-138

Springer Publishing Company

Access to resources Recommend Favorite